Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert D. Thompson is active.

Publication


Featured researches published by Robert D. Thompson.


Veterinary Immunology and Immunopathology | 2010

Lipopolysaccharide and TNF-α modify adenosine A2A receptor expression and function in equine monocytes

Wan-chun Sun; Londa J. Berghaus; James N. Moore; David J. Hurley; Michel L. Vandenplas; Robert D. Thompson; Joel Linden

Stimulation of adenosine A(2A) receptors results in anti-inflammatory effects in a variety of cell types. Lipopolysaccharide (LPS) and pro-inflammatory cytokines, such as TNF-alpha and IL-1, have been reported to up-regulate the expression of adenosine A(2A) receptors and thereby enhance the functional activity of adenosine A(2A) receptors in human and murine monocyte/macrophage cell lines and in monocytes/macrophages isolated from those species. In this study, we investigated the effects of LPS and TNF-alpha on the expression and functional activity of adenosine A(2A) receptors in isolated equine peripheral blood monocytes. The results of this study indicate that LPS and TNF-alpha up-regulate the transcription of adenosine A(2A) receptors for up to 24h; the response to LPS was of greater magnitude than the response to TNF-alpha. In this study, incubation with LPS, but not with TNF-alpha, resulted in down-regulation of adenosine A(3) receptor mRNA expression. Furthermore, incubation of these cells with LPS significantly increases the surface density of adenosine A(2A) receptors, and incubation with low concentrations of either LPS or TNF-alpha significantly increases the potency of the adenosine A(2A) receptor agonist, ATL313, to inhibit LPS-induced production of TNF-alpha. These findings suggest that the increased expression of adenosine A(2A) receptors and the enhanced functional potency of adenosine A(2A) receptor agonists after exposure to pro-inflammatory substances such as LPS or TNF-alpha may render adenosine A(2A) receptor agonists particularly important in the treatment of the systemic inflammatory response syndrome that occurs secondary to endotoxemia and bacterial infections in adult horses and neonatal foals.


Veterinary Immunology and Immunopathology | 2010

Differential modulation of lipopolysaccharide-induced expression of inflammatory genes in equine monocytes through activation of adenosine A2A receptors☆

Wan-chun Sun; James N. Moore; David J. Hurley; Michel L. Vandenplas; Barbara P. Fortes; Robert D. Thompson; Joel Linden

Adenosine is an endogenous nucleoside that has potent receptor-mediated immunomodulatory effects on macrophage/monocyte function. In this study, we determined the effects of an adenosine A(2A) receptor agonist, ATL313, on the expression of mRNAs for four pro-inflammatory mediators, IL-1beta, IL-8, COX-2, and TNF-alpha, and the mRNA and protein for the anti-inflammatory cytokine, IL-10 in equine monocytes incubated with lipopolysaccharide (LPS). The results indicate that ATL313 significantly reduces LPS-induced expression of COX-2 and TNF-alpha, enhances the expression of IL-10 and IL-8, but does not alter the expression of IL-1beta. These effects of ATL313 were reversed by co-incubation with the selective adenosine A(2A) antagonist ZM241385, and were mimicked by the cAMP analogue dibutyryl cAMP. These differential effects of adenosine A(2A) receptor activation were in contrast to those obtained using the P38 MAPK inhibitor, SB203580, which nearly abolished all LPS-induced changes in mRNA expression as well as the production of TNF-alpha protein. These findings, which indicate that adenosine A(2A) receptor activation modulates the transcription of several, but not all, pro-inflammatory mediators and exerts a synergistic effect on the induction of at least one anti-inflammatory cytokine, suggest that selective adenosine A(2A) agonists may reduce the early pro-inflammatory effects of endotoxemia in horses.


Archive | 2006

Derivatives of 8-substituted xanthines

Guoquan Wang; Jayson M. Rieger; Robert D. Thompson


Archive | 2009

Intrathecal treatment of neuropathic pain with a2ar agonists

Linda R. Watkins; Lisa C. Loram; Mark Hutchinson; Robert D. Thompson; Anthony Beauglehole; Frank W. Schmidtmann; Jayson M. Rieger


Archive | 2006

Pyridyl substituted xanthines

Guoquan Wang; Jayson M. Rieger; Robert D. Thompson


Archive | 2007

Substituted 8-[6-amino-3-pyridyl]xanthines

Guoquan Wang; Robert D. Thompson; Jayson M. Rieger


Archive | 2006

Pyrazolyl substituted xanthines

Guoquan Wang; Jayson M. Rieger; Robert D. Thompson


Archive | 2006

Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines

Guoquan Wang; Jayson M. Rieger; Robert D. Thompson


Archive | 2008

Therapeutic agent for glaucoma containing adenosine derivative as active ingredient

Atsushi Shimazaki; Noriko Kawabata; Tomoko Kirihara; Jayson M. Rieger; Robert D. Thompson


Archive | 2007

Substituted aryl piperidinylalkynyladenosines as a2ar agonists

Jayson M. Rieger; Robert D. Thompson

Collaboration


Dive into the Robert D. Thompson's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joel Linden

University of Virginia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gail W. Sullivan

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Lauren Murphree

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge